Sie suchten nach: HyClone+products+(Cytiva)

33 229 Ergebnisse wurden gefunden

Suchergebnis einschränken: Sortieren nach

Sort Results

Listenansicht Hybridansicht

Vergleichen(0) Entfernen

Bewerten Sie das Suchergebnis

HyClone™ Classical Liquid Media: Medium 199, HyClone products (Cytiva)

Lieferant: HyClone products (Cytiva)

Beschreibung: HyClone Medium 199 is manufactured using ISO 9001:2000-certified processes

HyClone™ AdvanceSTEM ES Qualified Amino Acids, HyClone products

Lieferant: HyClone products (Cytiva)

Beschreibung: HyClone AdvanceSTEM ES Qualified Amino Acids have been optimized for growth of embryonic cell cultures.

HyClone™ Dialysed Foetal Bovine Serum, US origin

Lieferant: HyClone products (Cytiva)

Beschreibung: Augment growth of cells with U.S.-sourced Cytiva HyClone Dialyzed Fetal Bovine Serum (FBS).

HEPES Buffer Solution 1 M, HyClone™

Artikel-Nr: (HYCLSH30237.01)

Lieferant: HyClone products (Cytiva)

Beschreibung: Maintain physiological pH in cell culture, despite changes in carbon dioxide concentration (produced by cellular respiration) with Cytiva HyClone HEPES solution.

VE: 1 * 100 mL

Zertifikate Sale!

N/A Each

HyClone AdvanceSTEM™ Stem Cell Media, Mesenchymal Stem Cell Expansion Kit, HyClone products (Cytiva)

Lieferant: HyClone products (Cytiva)

Beschreibung: AdvanceSTEM™ Mesenchymal Stem Cell Basal Medium and Mesenchymal Stem Cell Growth Supplement have been formulated to support expansion and maintenance of undifferentiated human mesenchymal stem cells (hMSCs).

HyClone™ Newborn Bovine Calf Serum, US Origin, Cytiva

Lieferant: HyClone products (Cytiva)

Beschreibung: Bovine calf serum products are excellent and cost-effective alternatives to fetal bovine serum (FBS). Bovine calf serum products contain exceptionally high levels of transferrin, which can provide three to four times as much available iron as FBS.

HyClone™ SFM4MAb media

Lieferant: HyClone products (Cytiva)

Beschreibung: HyClone™ SFM4MAb media was developed through the Metabolic Pathway Design approach to increase process yields for manufacturing of human and humanised recombinant antibodies for therapeutic use.